The oncologist 2022 Mar 28
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
ABSTRACT
Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, -mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.
Related Questions
New answer by Medical Oncologist at Cleveland Clinic (March 26, 2024)
Yes, I would offer capivasertib/fulvestrant to a patient with PTEN mutation who has progressed on prior fulvestrant/ribociclib. Such patients are not represented in CAPItello-...